CN102861050A - Application of Houttuynoid A in medicine for treating pancreatic cancer - Google Patents
Application of Houttuynoid A in medicine for treating pancreatic cancer Download PDFInfo
- Publication number
- CN102861050A CN102861050A CN2012104180786A CN201210418078A CN102861050A CN 102861050 A CN102861050 A CN 102861050A CN 2012104180786 A CN2012104180786 A CN 2012104180786A CN 201210418078 A CN201210418078 A CN 201210418078A CN 102861050 A CN102861050 A CN 102861050A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- medicine
- pancreatic cancer
- application
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 25
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 17
- FHNVKCJCSKWUFS-YLUJEXTNSA-N 4-[5,7-dihydroxy-4-oxo-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-yl]-7-hydroxy-2-nonyl-1-benzofuran-3-carbaldehyde Chemical compound C=12C(C=O)=C(CCCCCCCCC)OC2=C(O)C=CC=1C=1OC2=CC(O)=CC(O)=C2C(=O)C=1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O FHNVKCJCSKWUFS-YLUJEXTNSA-N 0.000 title abstract description 42
- 208000008443 pancreatic carcinoma Diseases 0.000 title abstract description 14
- 201000002528 pancreatic cancer Diseases 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 16
- 229930190556 houttuynoid Natural products 0.000 claims description 4
- 230000012010 growth Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 12
- 230000001093 anti-cancer Effects 0.000 description 6
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 230000003602 anti-herpes Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 240000000691 Houttuynia cordata Species 0.000 description 3
- 235000013719 Houttuynia cordata Nutrition 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of Houttuynoid A in preparing medicine for treating pancreatic cancer, which belongs to the technical field of new application of the medicine. According to the assessment on the antineoplastic activity through in-vitro MTT method, Houttuynoid A has an obvious inhibiting effect on the growth of human pancreatic cancer cell strains PANC-1 and BXPC-3. Therefore, Houttuynoid A can be used for preparing the medicine for preventing pancreatic cancer, and has a favorable development and application prospect. The application of the Houttuynoid A in preparing the medicine for treating pancreatic cancer, which is provided by the invention, is disclosed for the first time, and because the skeleton type belongs to brand-new skeleton type, the inhibiting activity of Houttuynoid A to pancreatic cancer cells is extremely strong.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid A, relate in particular to the application of Houttuynoid A in the anti-cancer of pancreas medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid A that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid A that the present invention relates in preparation treatment cancer of pancreas medicine, because framework types belongs to brand-new framework types, and its inhibition for pancreatic cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously cancer of pancreas obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid A in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid A in the anti-cancer of pancreas medicine of preparation, and the structural formula of Houttuynoid A is shown in formula I:
Formula I
The present invention finds by external MTT anti-tumor activity evaluation, and Houttuynoid A also has significant inhibitory action to the growth of human pancreas cancer cell strain PANC-1 and BXPC-3, suppresses the IC of this 2 strain Growth of Cells
50Value is respectively 1.04 ± 0.17 μ M and 1.22 ± 0.21 μ M.Therefore, Houttuynoid A can for the preparation of anti-cancer of pancreas medicine, have good development prospect.
Belong to open first for the purposes of the Houttuynoid A that the present invention relates in preparation treatment cancer of pancreas medicine, because framework types belongs to brand-new framework types, and its inhibition for pancreatic cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously cancer of pancreas obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid A involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid A tablet involved in the present invention:
Get 20 and digest compound Houttuynoid A, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid A capsule involved in the present invention:
Get 20 and digest compound Houttuynoid A, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid A to the growth inhibited effect of human pancreas cancer cell strain
1. method: the cell that is in the growth logarithmic (log) phase: human pancreas cancer cell strain PANC-1 and BXPC-3(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid A of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5 mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid A has significant inhibitory action to the growth of human pancreas cancer cell strain PANC-1 and BXPC-3.This chemical compound suppresses the IC of human pancreas cancer cell strain PANC-1 and BXPC-3 growth
50Value is respectively 1.04 ± 0.17 μ M and 1.22 ± 0.21 μ M.
Shown by above-described embodiment, Houttuynoid A of the present invention has good inhibitory action to the growth of human pancreas cancer cell strain PANC-1 and BXPC-3.Prove thus, it is active that Houttuynoid A of the present invention has anti-cancer of pancreas, can be for the preparation of anti-cancer of pancreas medicine.
Claims (1)
1.Houttuynoid the application of A in treatment cancer of pancreas medicine, described compound H outtuynoid A structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104180786A CN102861050A (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in medicine for treating pancreatic cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104180786A CN102861050A (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in medicine for treating pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102861050A true CN102861050A (en) | 2013-01-09 |
Family
ID=47440368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104180786A Pending CN102861050A (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in medicine for treating pancreatic cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861050A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655552A (en) * | 2013-12-04 | 2014-03-26 | 常州科立信医疗器械有限公司 | Application of Manzamenone O in pancreas cancer treatment medicines |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070080329A (en) * | 2006-02-07 | 2007-08-10 | 인제대학교 산학협력단 | Cancer prevention and treatment composition containing Eungchocho extract |
| US20120046237A1 (en) * | 1998-04-08 | 2012-02-23 | Theoharides Theoharis C | Compositions for protection against superficial vasodilator flush syndrome, and methods of use |
| CN102448455A (en) * | 2009-03-31 | 2012-05-09 | 雀巢产品技术援助有限公司 | Use of flavonoids for increasing the bioavailability of hesperetin |
-
2012
- 2012-10-27 CN CN2012104180786A patent/CN102861050A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120046237A1 (en) * | 1998-04-08 | 2012-02-23 | Theoharides Theoharis C | Compositions for protection against superficial vasodilator flush syndrome, and methods of use |
| KR20070080329A (en) * | 2006-02-07 | 2007-08-10 | 인제대학교 산학협력단 | Cancer prevention and treatment composition containing Eungchocho extract |
| CN102448455A (en) * | 2009-03-31 | 2012-05-09 | 雀巢产品技术援助有限公司 | Use of flavonoids for increasing the bioavailability of hesperetin |
Non-Patent Citations (1)
| Title |
|---|
| 陈庆华等: "鱼腥草总黄酮的提取工艺研究", 《湖北中医学院学报》, vol. 9, no. 2, 30 June 2007 (2007-06-30), pages 29 - 30 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655552A (en) * | 2013-12-04 | 2014-03-26 | 常州科立信医疗器械有限公司 | Application of Manzamenone O in pancreas cancer treatment medicines |
| CN103655552B (en) * | 2013-12-04 | 2015-05-06 | 滨州医学院 | Application of Manzamenone O in pancreas cancer treatment medicines |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861059B (en) | Application of Houttuynoid D in pancreatic cancer treatment medicine | |
| CN102861050A (en) | Application of Houttuynoid A in medicine for treating pancreatic cancer | |
| CN102872093B (en) | Application of Houttuynoid E in medicine for treating pancreatic cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102861058B (en) | Application of Houttuynoid D in cholangiocarcinoma treatment medicine | |
| CN102872148B (en) | Application of Houttuynoid D in medicament for treating tongue cancer | |
| CN102872122B (en) | Application of Houttuynoid B in medicament for treating pancreatic cancer | |
| CN102861061B (en) | Application of Houttuynoid B in cholangiocarcinoma treatment medicine | |
| CN102861049B (en) | Application of Houttuynoid A in medicine for treating liver cancer | |
| CN102861056B (en) | Application of Houttuynoid A in endometrial cancer treatment medicine | |
| CN102872149B (en) | Application of Houttuynoid B in medicament for treating cecum cancer | |
| CN102861052B (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN102861062B (en) | Application of Houttuynoid C in endometrial cancer treatment medicine | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102872089A (en) | Application of Houttuynoid E in medicines for treating skin cancer | |
| CN102861048A (en) | Application of Houttuynoid A in medicine for treating nasopharyngeal carcinoma | |
| CN102872111A (en) | Application of Houttuynoid C in medicament for treating pancreatic cancer | |
| CN102861051A (en) | Application of Houttuynoid A in medicine for treating renal cancer | |
| CN102872139A (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102885844A (en) | Application of Houttuynoid B in medicine for treating tongue cancer | |
| CN102895247A (en) | Application of Houttuynoid B to medicament for treating oophoroma | |
| CN103120679A (en) | Application of Aphanamixoid A in medicine for treating tongue cancer | |
| CN102872151A (en) | Application of Houttuynoid B in medicament for treating nasopharyngeal cancer | |
| CN102861077A (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102872108A (en) | Application of Houttuynoid A in medicine for treating bile duct cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130109 |